JO3362B1 - الحفظ بالتبريد لخلايا سرطان الموت الخلوي المبرمج للاستعمال في العلاج المناعي ضد السرطان - Google Patents

الحفظ بالتبريد لخلايا سرطان الموت الخلوي المبرمج للاستعمال في العلاج المناعي ضد السرطان

Info

Publication number
JO3362B1
JO3362B1 JOP/2014/0365A JOP20140365A JO3362B1 JO 3362 B1 JO3362 B1 JO 3362B1 JO P20140365 A JOP20140365 A JO P20140365A JO 3362 B1 JO3362 B1 JO 3362B1
Authority
JO
Jordan
Prior art keywords
cryopreservation
cancer
immunotherapy
cells
apoptotic
Prior art date
Application number
JOP/2014/0365A
Other languages
English (en)
Inventor
Moserova Irena
Truxova Iva
FUCIKOVA Jitka
Rozkova Daniela
Spisek Radek
Pokorna Katerina
Koci Lenka
Original Assignee
Sotio As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sotio As filed Critical Sotio As
Application granted granted Critical
Publication of JO3362B1 publication Critical patent/JO3362B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/122—Preservation or perfusion media
    • A01N1/125—Freeze protecting agents, e.g. cryoprotectants or osmolarity regulators
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/16—Physical preservation processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4205—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4274—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
    • A61K40/4275—Prostate specific antigen [PSA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4274—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
    • A61K40/4276—Prostate specific membrane antigen [PSMA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/58—Prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Environmental Sciences (AREA)
  • Dentistry (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

يتم في هذه الوثيقة وصف طريقة يمكن الاعتماد عليها لإعداد لقاح فعال مفيد لعلاج مناعي تتضمن الطريقة خطوة الحفظ بالتبريد لجمهرة خلايا لتخضع لموت الخلايا المناعي، واستخدام مثل هذه الخلايا لتنشيط الخلايا الجذعية لاستخدامها في العلاج المناعي. في تجسيد معين، تتضمن الطريقة الحفظ بالتبريد لخلايا سرطانية لتخضع لموت خلايا، والتي يمكن استخدامها لإعداد تركيبة دوائية لعلاج مناعي ضد السرطان.
JOP/2014/0365A 2013-12-27 2014-12-17 الحفظ بالتبريد لخلايا سرطان الموت الخلوي المبرمج للاستعمال في العلاج المناعي ضد السرطان JO3362B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14/142,448 US9562219B2 (en) 2013-12-27 2013-12-27 Cryopreservation of apoptotic cancer cells for use in immunotherapy against cancer

Publications (1)

Publication Number Publication Date
JO3362B1 true JO3362B1 (ar) 2019-03-13

Family

ID=52292898

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2014/0365A JO3362B1 (ar) 2013-12-27 2014-12-17 الحفظ بالتبريد لخلايا سرطان الموت الخلوي المبرمج للاستعمال في العلاج المناعي ضد السرطان

Country Status (9)

Country Link
US (5) US9562219B2 (ar)
KR (1) KR20160113611A (ar)
AR (1) AR100666A1 (ar)
AU (1) AU2014372723A1 (ar)
CA (1) CA2935126A1 (ar)
JO (1) JO3362B1 (ar)
MX (1) MX2016008432A (ar)
TW (1) TW201528948A (ar)
WO (1) WO2015097037A1 (ar)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9562219B2 (en) 2013-12-27 2017-02-07 SOTIO a.s. Cryopreservation of apoptotic cancer cells for use in immunotherapy against cancer
CN109310723A (zh) * 2016-06-06 2019-02-05 Sotio公司 癌症的免疫疗法
KR102256337B1 (ko) * 2017-10-17 2021-05-26 (주)노터스생명과학 조직이식을 위한 세포배양액을 포함하는 면역억제제
CN111801115A (zh) 2018-01-25 2020-10-20 Sotio公司 与化学疗法并行的树突状细胞疫苗接种
KR102890621B1 (ko) 2018-01-25 2025-11-26 소티오 에이.에스. 화학요법에 순차적인 수지상 세포 백신접종
WO2020187975A1 (en) 2019-03-19 2020-09-24 SOTIO a.s. Patient selection for treatment with dendritic cell vaccination
JP7340240B2 (ja) * 2019-08-26 2023-09-07 学校法人関西医科大学 細胞又は組織にアポトーシスを誘導する方法
JP2023504659A (ja) 2019-12-03 2023-02-06 ニューボーゲン，インコーポレイティド 腫瘍細胞ワクチン
WO2022087110A1 (en) * 2020-10-20 2022-04-28 The Regents Of The University Of California Attenuated cancer cells and methods related thereto
EP4291638A1 (en) 2021-02-12 2023-12-20 SCTbio a.s. Patient selection for treatment with dendritic cell vaccination
WO2023017191A1 (en) 2021-08-13 2023-02-16 Cytune Pharma Il-2/il-15rbetagamma agonist combination with antibody-drug conjugates for treating cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002504322A (ja) 1998-02-20 2002-02-12 ザ ロックフェラー ユニバーシティー 樹状細胞に対するアポトーシス細胞介在抗原提示
EP1078043A1 (en) * 1998-05-11 2001-02-28 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale New apoptotic bodies, monocyte derived cells containing the same, a process for their preparation and their uses as vaccines
WO2003012085A1 (en) * 2001-07-30 2003-02-13 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Antigen presenting cells, method for their preparation and their use for cancer vaccines
US20060140983A1 (en) 2004-10-25 2006-06-29 Baylor Research Institute Dendritic cells loaded with heat shocked melanoma cell bodies
WO2006095330A2 (en) 2005-03-10 2006-09-14 Yeda Research And Development Co. Ltd. Methods and immunogenic cell preparations for treating antigen-associated diseases
WO2011101796A1 (en) 2010-02-19 2011-08-25 Cadila Pharmaceuticals Limited A pharmaceutical composition of killed cells with substantially retained immunogenicity
EP2543386A1 (en) 2011-07-05 2013-01-09 Sotio a.s. Means and methods for active cellular immunotherapy of cancer by using tumor cells killed by high hydrostatic pressure
US20130011438A1 (en) 2011-07-05 2013-01-10 SOTIO a.s. Means And Methods For Active Cellular Immunotherapy Of Cancer By Using Tumor Cells Killed By High Hydrostatic Pressure and Dendritic Cells
US9562219B2 (en) 2013-12-27 2017-02-07 SOTIO a.s. Cryopreservation of apoptotic cancer cells for use in immunotherapy against cancer

Also Published As

Publication number Publication date
US10155033B2 (en) 2018-12-18
US20190070278A1 (en) 2019-03-07
US20170232086A1 (en) 2017-08-17
US20180125956A1 (en) 2018-05-10
AU2014372723A1 (en) 2016-06-16
US20200147191A1 (en) 2020-05-14
US10561717B2 (en) 2020-02-18
CA2935126A1 (en) 2015-07-02
US9562219B2 (en) 2017-02-07
TW201528948A (zh) 2015-08-01
US20150184130A1 (en) 2015-07-02
US9895430B2 (en) 2018-02-20
WO2015097037A1 (en) 2015-07-02
KR20160113611A (ko) 2016-09-30
MX2016008432A (es) 2016-10-28
AR100666A1 (es) 2016-10-26

Similar Documents

Publication Publication Date Title
JO3362B1 (ar) الحفظ بالتبريد لخلايا سرطان الموت الخلوي المبرمج للاستعمال في العلاج المناعي ضد السرطان
IL289821B (en) Compositions and methods for immunotherapy
IL282352B (en) Methods for producing autologous t cells useful to treat b cell malignancies and other cancers and compositions thereof
IL246645A0 (en) Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells
CL2015002562A1 (es) Anticuerpos e inmunoconjugados anti-b7-h4
TWD170564S (zh) 杯子
IL285527A (en) Compositions and methods for immunotherapy
TWD170352S (zh) 項鍊
TWD170983S (zh) 錶
MX385585B (es) Anticuerpos anti-c10orf54 y usos de los mismos.
TWD176223S (zh) 安全剃刀
TWD171860S (zh) 錶
TWD171450S (zh) 錶
BR112016017402A2 (pt) fusões anti-pcsk9~glp-1 e métodos para uso
TWD189671S (zh) 電池
TWD173859S (zh) 電連接器
IL250495B (en) Stem cell compositions and methods of producing stem cells for therapeutic applications
TWD170777S (zh) 錶
TWD171710S (zh) 端子
TWD182065S (zh) 剪刀(一)
TWD165187S (zh) 讀卡機
IL245306A0 (en) Compositions and methods for producing genetically modified animals
TWD172410S (zh) 電連接器
SG11201903231WA (en) Microbioreactor module
CL2015001539A1 (es) Método para producir células dendríticas tolerogénicas autólogas (toldcs) con antígenos específicos; toldcs obtenidas por dicho método; y su uso en la preparación de un medicamento útil para el tratamiento de lupus eritematoso sistémico (les)